Literature DB >> 15205293

Criteria influencing the clinical uptake of pharmacogenomic strategies.

Jai Shah1.   

Abstract

Keywords:  Genetics and Reproduction

Mesh：

Substances：

Year:  2004        PMID： 15205293      PMCID： PMC428522          DOI： 10.1136/bmj.328.7454.1482

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

Review 1.  Ethical and legal implications of pharmacogenomics.

Authors:  M A Rothstein; P G Epps
Journal:  Nat Rev Genet       Date:  2001-03       Impact factor: 53.242

Review 2.  The complexities of predictive genetic testing.

Authors:  J P Evans; C Skrzynia; W Burke
Journal:  BMJ       Date:  2001-04-28

3.  Clinical pharmacogenomics: applications in pharmaceutical R&D.

Authors:  R M. Norton
Journal:  Drug Discov Today       Date:  2001-02-01       Impact factor: 7.851

4.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

5.  A regulatory protocol for pharmacogenomics services.

Authors:  L A Bristol
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

6.  Preventing toxicity with a gene test.

Authors:  Eliot Marshall
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

7.  Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare.

Authors:  Jai Shah
Journal:  Nat Biotechnol       Date:  2003-07       Impact factor: 54.908

Review 8.  Ethical perspectives on pharmacogenomic profiling in the drug development process.

Authors:  Amalia M Issa
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 9.  Drug methylation in cancer therapy: lessons from the TPMT polymorphism.

Authors:  Eugene Krynetski; William E Evans
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

10.  Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis.

Authors:  Hisashi Moriguchi; Takamoto Uemura; Makoto Kobayashi; Raymond T Chung; Chifumi Sato
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425
View more
  12 in total

1.  Delivering a pharmacogenetic service: is there a role for genetic counselors?

Authors:  Alice Callard; William Newman; Katherine Payne
Journal:  J Genet Couns       Date:  2011-11-04       Impact factor: 2.537

2.  Pharmacogenetic testing: Current Evidence of Clinical Utility.

Authors:  Jivan Moaddeb; Susanne B Haga
Journal:  Ther Adv Drug Saf       Date:  2013-08-01

3.  Testing patients to allow tailored drug treatment.

Authors:  Peter Leman; Shaun Greene
Journal:  BMJ       Date:  2005-02-12

Review 4.  Pharmacogenetics, the next challenge for pharmacy?

Authors:  Jessica P Clemerson; Katherine Payne; Paul Bissell; Claire Anderson
Journal:  Pharm World Sci       Date:  2006-09-27

Review 5.  The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Authors:  Mafalda M Dias; Michael J Sorich; Andrew Rowland; Michael D Wiese; Ross A McKinnon
Journal:  Pharm Res       Date:  2017-02-24       Impact factor: 4.200

6.  Primary care physicians' knowledge of and experience with pharmacogenetic testing.

Authors:  S B Haga; W Burke; G S Ginsburg; R Mills; R Agans
Journal:  Clin Genet       Date:  2012-07-03       Impact factor: 4.438

Review 7.  Understanding patient and provider perceptions and expectations of genomic medicine.

Authors:  Michael J Hall; Andrea D Forman; Susan V Montgomery; Kim L Rainey; Mary B Daly
Journal:  J Surg Oncol       Date:  2014-07-03       Impact factor: 3.454

8.  CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.

Authors:  Natasa Djordjevic; Dragana Dragas Milovanovic; Marija Radovanovic; Ivan Radosavljevic; Slobodan Obradovic; Mihajlo Jakovljevic; Dragan Milovanovic; Jasmina R Milovanovic; Slobodan Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-14       Impact factor: 2.953

9.  Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.

Authors:  Graham Powell; Emily A F Holmes; Catrin O Plumpton; Adele Ring; Gus A Baker; Ann Jacoby; Munir Pirmohamed; Anthony G Marson; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2015-08-22       Impact factor: 4.335

10.  Adaptation and development of software simulation methodologies for cardiovascular engineering: present and future challenges from an end-user perspective.

Authors:  V Díaz-Zuccarini; A J Narracott; G Burriesci; C Zervides; D Rafiroiu; D Jones; D R Hose; P V Lawford
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2009-07-13       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.